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A Cellular Mechanism
for the Bidirectional Pain-Modulating
Actions of Orphanin FQ/Nociceptin
OFQ/N produces hyperalgesia (increasing pain) or anal-
gesia (reducing pain), as has been critically reviewed in
four recent articles (Henderson and McKnight, 1997;
Civelli et al., 1998; Darland et al., 1998; Yamamoto et
al., 1999). Adding to this controversy is the lack of a
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We recently characterized the cellular mechanisms
underlying the analgesic opioid effect mediated by m
opioid receptors and the m-opposing action of the k
Summary
opioid receptor in the nucleus raphe magnus (NRM) (Pan
et al., 1997). This brainstem region directly modulates
Orphanin FQ/nociceptin (OFQ/N) and its receptor
pain transmission at the spinal cord and is a critical
share substantial structural features and cellular ac-
supraspinal component mediating opioid analgesia (Bas-
tions with classic opioid peptides and receptors, but
baum and Fields, 1984; Fields et al., 1991). Thus, opioids
have distinct pharmacological profiles and behavioral
acting on the m receptor produce analgesia by inhibiting
effects. Currently there is an active debate about
one cell type (secondary cells) in the nucleus and disin-
whether OFQ/N produces hyperalgesia or analgesia.
hibiting the other major cell type (primary cells). In con-
Using a well-defined brainstem pain-modulating cir-
trast, agonists at the k receptor directly inhibit primary
cuit, we show that OFQ/N can cause either an apparent
cells that are disinhibited by m agonists and thereby
hyperalgesia by antagonizing m opioid±induced anal-
attenuate m receptor±mediated analgesia (Pan et al.,
gesia or a net analgesic effect by reducing the hyperal-
1990, 1997). As OFQ/N and its receptor are densely
gesia during opioid abstinence. It presumably pro-
expressed in the NRM (Schulz et al., 1996; Monteillet-
duces these two opposite actions by inhibiting two
Agius et al., 1998), knowledge of the mechanisms under-
distinct groups of neurons whose activation mediates
lying the behavioral actions of m and k receptors in the
the two effects of opioid administration. OFQ/N antag-
NRM provides a unique target system to investigate the
onism of the hyperalgesia may have significance for
function of the OFQ/N system in opioid modulation of
the treatment of opioid withdrawal and sensitized pain.
pain. In this study, we used a combination of electro-
physiological studies at the cellular level in vitro and
Introduction behavioral studies in rats in vivo to characterize the
cellular actions of OFQ/N on the two types of NRM cells
Orphanin FQ or nociceptin (OFQ/N), a heptadecapeptide and to determine how its cellular actions modulate pain
discovered five years ago (Meunier et al., 1995; Rein- behavior.
scheid et al., 1995), is an endogenous agonist for the
orphan opioid receptor identified a year earlier (Bunzow Results
et al., 1994; Chen et al., 1994; Fukuda et al., 1994; Moller-
eau et al., 1994; Wang et al., 1994; Wick et al., 1994). OFQ/N Hyperpolarizes Both Primary Cells
Both OFQ/N and its receptor have extensive sequence and Secondary Cells
homology to endogenous opioid peptides and the three First, we examined the cellular actions of OFQ/N on the
known opioid receptors, m, k, and d, respectively (Meu- two cell types in the NRM using brain slice preparations
nier, 1997; Civelli et al., 1998). OFQ/N and its receptor in vitro. Visualized whole-cell patch clamp recordings
are widely distributed in the CNS and have broad overlap were made from NRM neurons identified as either a
with endogenous opioid peptides and receptors (Anton primary cell or a secondary cell according to the criteria
et al., 1996; Monteillet-Agius et al., 1998). Since its dis- described before (Pan et al., 1990). In brief, primary cells
covery, OFQ/N has been the subject of a large and have a wider action potential, more negative resting
growing number of studies intended to understand its membrane potential, and are not inhibited by m agonists;
physiological role in the brain and its functional relation- secondary cells have a shorter action potential, are often
ship to the classic opioid system. As with the original firing spontaneously, and are mostly hyperpolarized by
reports (Meunier et al., 1995; Reinscheid et al., 1995),
m agonists.
most of these studies have focused on OFQ/N's role in We found that OFQ/N (100 nM) inhibited both cell
pain modulation and in opioid-induced analgesia. How- types through a membrane hyperpolarization in current
ever, despite consistent, opioid-like inhibitory actions clamp (primary cells, 7.3 6 1.9 mV, n 5 6; secondary
of OFQ/N at the cellular level in various brain sites (Hen- cells, 8.3 6 1.3 mV, n 5 10). In primary cells under
derson and McKnight, 1997; Darland et al., 1998), the voltage clamp, OFQ/N (100 nM) produced an inhibition
effect of OFQ/N on pain behavior and opioid analgesia through an outward current (37.8 6 7.0 pA, n 5 19). In
remains controversial. A contentious issue is whether 11 of those primary cells in which both OFQ/N and the
k agonist U69593 were tested, 5 (45%) were also inhib-
ited by U69593 (100 nM, 35.8 6 8.2 pA, Figure 1A).³ To whom correspondence should be addressed (e-mail: zzp@
itsa.ucsf.edu). The other 6 primary cells inhibited by OFQ/N were not
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Figure 2. OFQ/N-Induced Increase of an Inwardly Rectifying Potas-
sium Conductance
(A) A current±voltage plot in the absence (open circle) and presence
(closed circle) of OFQ/N (100 nM) in two extracellular potassium
concentrations. Arrows indicate reversal potentials.
(B) Subtracted currents induced by OFQ/N from (A). Note the inward
rectification.
equilibrium potential in both cell types (primary cell,
Erev 5 296.4 6 2.3 mV, n 5 15; secondary cell, Erev 5
Figure 1. OFQ/N-Produced Inhibition of NRM Cells 2104.0 6 2.5 mV, n 5 12, Figure 2A). When the extracel-
(A) Outward currents induced by the k receptor agonist U69593 and lular potassium concentration (2.5 mM) was raised to
by OFQ/N in the same primary cell under voltage clamp (holding 6.5 mM and 10.5 mM, the reversal potential was shifted
potential 5 260 mV).
to less negative potentials with a relationship in line with(B) Outward currents produced by both OFQ/N and [met]enkephalin
the Nernst equation (slope 5 256.8). In addition, OFQ/Nacting on the m receptor (Pan et al., 1990) in a secondary cell.
produced a larger conductance increase in the inward(C) A dose±response graph for the OFQ/N inhibition. Four data points
(mean 6 SE) from each of 7 cells of both types were pooled and direction (2.4 6 0.5 nS measured between 2110 and
fitted with the logistic equation. 2120 mV) than in the outward direction (0.8 6 0.1 nS
between 270 and 280 mV, n 5 22, p , 0.001, paired
Student's t test, Figure 2B). Together, these results dem-
onstrate that OFQ/N inhibits both k-sensitive primaryaffected by the k agonist. In secondary cells, OFQ/N
cells and m-sensitive secondary cells in the NRM by(100 nM) induced an outward current of 19.2 6 2.7 pA
increasing an inwardly rectifying potassium conduc-(n 5 13). In those secondary cells in which [met]enkeph-
tance.alin was also tested (n 5 7), [met]enkephalin (10 mM)
acting at the m receptor, as we reported before (Pan et
OFQ/N Occludes Both m and kal., 1990), produced a similar inhibition (20.9 6 1.6 pA,
Receptor±Mediated Effectsn 5 7, Figure 1B). The OFQ/N effect was dose dependent
We previously showed that activation of m receptorsand had a similar dose range in both cell types. The
inhibits secondary cells by increasing an inwardly recti-maximum inhibition dose was around 300 nM with an
fying potassium conductance (Pan et al., 1990) and thatestimated EC50 of 31 nM (Figure 1C). The nonselective
k receptor±mediated inhibition of primary cells is alsoopioid receptor antagonist naloxone (1 mM) did not
induced through an increase in an inwardly rectifyingchange the inhibitory effect of OFQ/N (56.0 6 11.4 pA
potassium conductance (Pan et al., 1997). To determinebefore and 54.3 6 9.8 pA after naloxone, n 5 4), nor did
whether OFQ/N inhibits these two cell types through thethe selective opioid receptor antagonists CTOP (m, 1
same potassium conductance, we examined the effectsmM), naltrindole (d, 1 mM), or norBNI (k, 100 nM) (n 5 3
of both OFQ/N and the respective opioid agonist on thefor each). This indicates that the OFQ/N-induced inhibi-
same cell. In a group of primary cells that were inhibitedtion is not mediated through any of the three classic
by the k agonist U69593 (300 nM) through an outwardopioid receptors.
current in voltage clamp (38.6 6 11.7 pA, n 5 8), OFQ/N
(300 nM) also inhibited these cells (85.1 6 21.0 pA, n 5 8,
Figure 3A). However, in the presence of OFQ/N, U69593OFQ/N Increases an Inwardly Rectifying
Potassium Conductance caused no further inhibition in the same cells (74.5 6
19.9 pA, n 5 8, Figure 3A). In secondary cells, both theVoltage clamp studies revealed that the OFQ/N-induced
outward current reversed its polarity near the potassium m agonist DAMGO (1 mM) and OFQ/N (300 nM) produced
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Figure 3. Occlusion of OFQ/N- and k or m Receptor±Mediated Inhi-
bitions in NRM Cells
(A) (Upper panel) Recording of membrane potential in a k-sensitive
primary cell under current clamp. In the presence of OFQ/N (300
nM), addition of the k agonist U69593 (300 nM) caused no further
hyperpolarization. (Lower panel) A histogram summarizing data from
a group of primary cells (n 5 8) under voltage clamp. There is no sig-
nificant difference between outward currents induced by OFQ/N
alone and by OFQ/N plus U69593 (p . 0.05, Student's t test).
(B) (Upper panel) Recording of membrane potential under current
clamp in a m-sensitive secondary cell. Spontaneous action poten-
tials are truncated. On top of the OFQ/N (300 nM)-induced hyperpo-
larization, the m agonist DAMGO (1 mM) produced no further inhibi-
tion. (Lower panel) A histogram showing group data in secondary
cells (n 5 9). The outward current induced by OFQ/N plus DAMGO
is not significantly different from that by OFQ/N alone (p . 0.05,
Student's t test).
an inhibition (27.0 6 5.2 pA and 29.4 6 9.1 pA, respec-
Figure 4. Antianalgesic Effect of OFQ/N in the NRMtively, n 5 9). However, similarly, DAMGO induced no
Tail flick latencies (mean 6 SE) were measured before (BL for base-inhibition beyond that elicited by OFQ/N in these cells
line, averages of six trials) and after drug microinjections (arrow) in(29.5 6 7.7 pA, n 5 9, Figure 3B). These findings suggest
six groups of rats (n 5 5 or 6 rats in each group). (A) Open circle,that OFQ/N activates the same inwardly rectifying potas-
DAMGO in the PAG and saline in the NRM; closed circle, DAMGO
sium conductance as that activated by the k receptor in in the PAG and OFQ/N in the NRM; open square, DAMGO in the
the primary cells and as that activated by the m receptor in PAG and OFQ/N 1 norBNI in the NRM; closed square, saline in the
PAG and OFQ/N in the NRM; (B) closed triangle, DAMGO in the PAGthe secondary cells. In other words, the OFQ/N inhibitory
and OFQ/N outside the NRM; open diamond, DAMGO in the PAGeffect will occlude the inhibitory effect of k agonists in
and CTOP in the NRM; and closed square, from (A). Asterisks denoteprimary cells or the inhibitory effect of m agonists in
data points in the group (closed circle) that are statistically differentsecondary cells.
from those in the group (open circle) (*, p , 0.05; **, p , 0.01;
ANOVA and post hoc analysis).
OFQ/N Antagonizes m Opioid-Induced Analgesia
We recently demonstrated that activation of the k-sensi-
tive, pain-inhibiting primary cells in the NRM is required flick latency quickly to the cutoff level (15 s) and com-
pletely blocked the tail flick reflex (Figure 4A, open circle,for the antinociception produced by m opioids applied
into the periaqueductal gray (PAG), which directly pro- n 5 5), indicating a strong antinociceptive effect by the
PAG DAMGO. Microinjection of OFQ/N (0.18 mg in 1 ml)jects to the NRM (Pan et al., 1997). In view of that,
OFQ/N-induced inhibition of these primary cells in the into the NRM by itself had no effect on the tail flick
latency (Figure 4A, closed square, n 5 5) but markedlyNRM, as described above, should antagonize this PAG
opioid±mediated antinociception. Furthermore, because reduced the PAG DAMGO-induced antinociception (Fig-
ure 4A, closed circle, n 5 5, p , 0.0001, a group by trialthe m-sensitive secondary cells in the NRM are inhibited
by m opioids in the PAG (Fields et al., 1991; Pan et al., interaction of an ANOVA for repeated measures and
post hoc analysis). This antagonizing effect of OFQ/N1997), this inhibition and the inhibition by OFQ/N would
be largely occluded, as we demonstrated at the cellular was not affected by the selective k receptor antagonist
norBNI (0.367 ng in 1 ml) microinjected into the NRMlevel above. Thus, OFQ/N inhibition of these secondary
cells should have no significant behavioral effect. We before the OFQ/N injection (Figure 4A, open square,
n 5 5). The same dose of norBNI has been shown tothen tested these predictions in lightly anesthetized rats
in vivo, using the tail flick response to noxious heat to completely block the inhibition of this PAG DAMGO-
induced antinociception by k agonists (Pan et al., 1997).measure pain threshold changes following drug microin-
jections locally into the PAG and the NRM. The k antagonist was used because the primary cells
whose activity underlies inhibition of the tail flick re-The selective m receptor agonist DAMGO (0.05 mg in
0.25 ml), microinjected into the PAG, increased the tail sponse by PAG DAMGO have functional k receptors but
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baseline level in about 30 min. In the other group of rats
(n 5 7), OFQ/N, microinjected into the NRM at the same
dose as before (0.18 mg in 1 ml), significantly attenuated
the hyperalgesia (Figure 5, closed circle, p , 0.01, an
ANOVA for repeated measures and post hoc analysis).
These results demonstrate that during naloxone-precip-
itated acute opioid withdrawal, OFQ/N produces an anti-
hyperalgesic, or a net analgesic effect (decreasing pain).
Note that this is opposite to the antianalgesic effect of
OFQ/N in the NRM observed following PAG application
of DAMGO.
Figure 5. Antihyperalgesic Effect of OFQ/N in the NRM Finally, to investigate the likely mechanism underlying
OFQ/N inhibition of opioid abstinence±induced hyperal-Morphine injection (i.v.) was followed by naloxone (i.v.) 26 min later
(arrowheads) and then by NRM microinjection (arrow) of either OFQ/N gesia, we again used brain slice preparations to examine
(closed circle, n 5 7 rats) or saline (open circle, n 5 7) 14 min after effects of naloxone-induced opioid abstinence on pri-
naloxone injection (*, p , 0.05; **, p , 0.01; ANOVA and post hoc mary and secondary cell types in vitro. In the treatment
analysis).
group, NRM slices were incubated in 100 mM morphine
for at least 2 hr, and then whole-cell patch clamp re-
cordings were made in the same concentration of mor-not m or d receptors (Pan et al., 1990). Microinjection of
phine throughout the experiments. In these morphine-OFQ/N at the same dose and volume into areas outside
treated slices, the resting membrane potential measuredthe NRM did not significantly change the PAG DAMGO-
immediately after break-in in current clamp was 273.1 6induced antinociception (Figure 4B, closed triangle, n 5
1.3 mV in all primary cells recorded (n 5 14) and 271.0 66) when compared to saline injection into the NRM
2.2 mV in primary cells (n 5 5) that were inhibited by(Figure 4A, open circle). This demonstrates a site-spe-
the k agonist U69593 at 300 nM (5.0 6 0.7 pA). Thosecific antagonizing effect of OFQ/N in the NRM. Addition-
resting membrane potentials were significantly moreally, previous evidence has suggested that the antinoci-
negative than those of k-sensitive primary cells fromception induced by the GABAA receptor antagonist
untreated slices without morphine in the control groupbicuculline applied into the PAG is mediated by m recep-
(263.8 6 1.2 mV, n 5 11, p , 0.01, Student's t test).tors in the NRM (Roychowdhury and Fields, 1996). In
Consistent with our previous report (Pan et al., 1990),this study, microinjection of the selective m antagonist
acute morphine (100 mM) did not affect primary cells inCTOP (2 mg in 1 ml) into the NRM completely blocked
normal slices (n 5 3). These results suggest that mor-the PAG DAMGO-induced antinociception (Figure 4B,
phine pretreatment produces a tonic inhibition of theseopen diamond, n 5 5). This finding further confirms
primary cells. In contrast, the morphine pretreatment didthe crucial role of NRM m receptors in the antinocicep-
not change the resting membrane potential in secondarytion induced through the PAG. Together, these results
cells that were inhibited by 1 mM DAMGO (5.5 6 1.3 pA,
demonstrate that OFQ/N antagonizes the m receptor±
n 5 8) in 100 mM morphine (253.1 6 0.8 mV in untreated
mediated antinociception in the NRM, probably by inhib-
slices, n 5 14 versus 252.7 6 0.8 mV in morphine-
iting the primary cells whose activity inhibits pain and
treated slices, n 5 8), nor did it change the percentage
is disinhibited by m agonists. Thus OFQ/N, under condi- of m-sensitive secondary cells that were spontaneously
tions of opioid-induced analgesia, produces an antianal- firing in slice preparations (8 out of 12 cells, or 67%, in
gesic, or hyperalgesic effect (increasing pain). normal slices without morphine and 5 out of 7 cells, or
71%, in morphine-treated slices in 100 mM morphine).
OFQ/N Attenuates Opioid Abstinence-Induced In control slices, acute morphine (100 mM) inhibited sec-
Hyperalgesia ondary cells through an outward current (14.2 6 0.2 pA,
In contrast to the analgesic action of primary cells, acti- n 5 4) and completely eliminated their spontaneous
vation of m-sensitive cells in the NRM mediates the hy- firing. These findings demonstrate that the m-sensitive
peralgesia observed during opioid withdrawal or absti- secondary cells developed tolerance to morphine fol-
nence in vivo (Bederson et al., 1990; Kaplan and Fields, lowing extended exposure in vitro.
1991). Our finding at the cellular level that OFQ/N inhibits To mimic the naloxone-precipitated opioid abstinence
m-sensitive secondary cells leads to the prediction that in vivo, naloxone was then applied to NRM cells from
OFQ/N will also oppose this opioid abstinence-related the morphine-treated slices. Having no significant effect
hyperalgesia at the behavioral level. We next tested this by itself in control slices, naloxone (1 mM) produced a
hypothesis using similar microinjection techniques in membrane depolarization or an inward current in both
rats in vivo. k-sensitive primary cells (220.4 6 7.4 pA, n 5 5) and
Systemic morphine (2 mg/kg, i.v.) was injected and m-sensitive secondary cells (25.7 6 0.4 pA, n 5 7) re-
followed 26 min later by systemic injection of naloxone corded in morphine-treated slices. Additionally, in the
(1 mg/kg, i.v.). As shown in Figure 5 in the control group presence of naloxone and morphine, OFQ/N (300 nM)
(open circle, n 5 7), naloxone reversed the morphine- again inhibited both the primary cells and the secondary
induced antinociception and shortened the tail flick la- cells through outward currents (17.2 6 5.1 pA, n 5 4,
tency to below the premorphine baseline level, indicat- and 22.8 6 7.2 pA, n 5 8, respectively).
ing a state of increased pain sensitivity, or hyperalgesia, Figure 6 illustrates the proposed cellular mechanisms
during this naloxone-induced acute opioid abstinence. underlying the two opposite pain-modulating actions of
OFQ/N in the NRM under different behavioral conditions.The tail flick latency then gradually recovered to the
Bidirectional Actions of Orphanin FQ/Nociceptin
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receptor systems in brain areas involved in pain modula-
tion (Schulz et al., 1996; Monteillet-Agius et al., 1998)
indicate that their differential behavioral effects on pain
result from their actions on functionally different groups
of neurons, as in the case of m and k receptors (Pan,
1998). Our finding that OFQ/N inhibits both k-sensitive
primary cells and m-sensitive secondary cells, the two
NRM cell types that have differential pain-modulating
actions, suggests that its action on pain behavior de-
pends on the behavioral state of an animal, or specifi-
cally, on which NRM cell type is activated in a certain
behavioral condition.
Figure 6. Schematic Illustration of the Mechanisms for the Bidirec-
tional Pain-Modulating Actions of OFQ/N in the NRM Antianalgesic Action of OFQ/N
OFQ/N receptors (O/N) are located in both m-sensitive secondary A hyperalgesic (pain-increasing) effect of OFQ/N was
cells and k-sensitive primary cells. Analgesic opioids acting on m
reported in both of the studies that first identified thereceptors inhibit the secondary cell and disinhibit the primary cell
peptide (Meunier et al., 1995; Reinscheid et al., 1995).whose activation produces analgesia. OFQ/N inhibits the analgesia
However, later studies found that similar systemic appli-through its inhibitory action predominantly on the activated primary
cell during opioid analgesia. Activation of the secondary cell contrib- cation of OFQ/N had no effect by itself but reduced
utes to the hyperalgesia during opioid withdrawal. OFQ/N antago- the analgesia produced by systemic administration of
nizes the hyperalgesia by inhibiting the relatively active secondary morphine (Mogil et al., 1996; Tian et al., 1997; King et
cell during opioid withdrawal. Presumably, primary cells receive a
al., 1998). Furthermore, it has been argued that the hy-GABA-ergic input from a subset of secondary cells.
peralgesic effect originally reported was the result of
OFQ/N antagonism of the analgesia mediated by endog-
enously released opioid peptides due to experimentalDiscussion
stress in animals (Mogil et al., 1996). Thus, this antianal-
gesic action of OFQ/N induces an apparent pain-increas-Our findings in this study demonstrate that application of
ing effect in stressed animals.OFQ/N in the NRM can have opposite pain-modulating
By characterizing both the behavioral effects and theactions depending on an animal's behavioral state. We
cellular actions of OFQ/N on neurons in a pain-modulatinghave observed that OFQ/N exerts an apparent hyperal-
circuit implicated in both m opioid± and stress-inducedgesic effect by blocking the analgesia produced by ex-
analgesia, the current study provides a likely cellularogenously applied opioid drugs. Conversely, in the con-
mechanism for the antianalgesic action of OFQ/N in thedition of opioid withdrawal or abstinence, it produces
NRM. In a previous study (Pan et al., 1997), we havean opposite, net analgesic effect.
shown that activation of k-sensitive primary cells in the
NRM mediates PAG DAMGO-induced antinociception.Cellular Action of OFQ/N
In light of the critical role of NRM in systemic opioid-The dominant cellular action of OFQ/N reported to date
induced analgesia and supporting evidence from manyin neurons from various brain sites, including the NRM
behavioral experiments in vivo (Fields et al., 1991), it isin the current study, is generally consistent, that is,
most likely that these primary cells also mediate themembrane hyperpolarization through opening of potas-
analgesia induced by systemically applied opioids. Con-sium channels (Connor et al., 1996; Vaughan and Chris-
versely, secondary cells are directly inhibited by m opi-tie, 1996; Vaughan et al., 1997; Meis and Pape, 1998;
oids in an analgesic state. Therefore, OFQ/N in the NRMWagner et al., 1998; Allen et al., 1999). In fact, OFQ/N
antagonizes PAG DAMGO-induced antinociception byshares similar cellular actions with the m, k, and d opioid
inhibiting those primary cells whose activity mediatesreceptors (North et al., 1987; Grudt and Williams, 1995;
the antinociception. Since secondary cells are inhibitedHenderson and McKnight, 1997). In the NRM, we have
by analgesic m opioids as well as by OFQ/N at the cellularfound that OFQ/N produces its inhibitory cellular action
level, and OFQ/N by itself in the NRM has no behavioralby activating the inwardly rectifying potassium conduc-
effect on pain, OFQ/N inhibition of m-sensitive second-tance that is also involved in k receptor±mediated inhibi-
ary cells occludes the cellular action of m opioids andtion in primary cells and in m receptor±mediated inhibi-
would not have a significant behavioral effect under thattion in secondary cells. Since OFQ/N occludes the
condition. Furthermore, we have demonstrated at thecellular effects of m and k opioid receptors, they likely
behavioral level that the PAG DAMGO-induced antinoci-share the same population of potassium channels. That
ception is mediated by the m opioid receptor in the NRM,indicates that OFQ/N can prevent the behavioral actions
as it is completely blocked by NRM application of themediated by the two opioid receptors through occlu-
m antagonist CTOP. Together, our results indicate thatsion. In addition, our finding of OFQ/N inhibition of both
OFQ/N can have a pain-increasing action by reversingNRM cell types at the cellular level provides the mecha-
the disinhibitory effect of m opioids (i.e., excitation ofnism for the general OFQ/N inhibition of firing in NRM
primary cells) that mediates the analgesia produced byneurons recorded extracellularly in rats in vivo (Heinricher
either exogenously applied opioid drugs or by endoge-et al., 1997).
nously released opioid peptides in conditions such asSimilar cellular actions and largely overlapping re-
gional distributions of the OFQ/N and classic opioid stress.
Neuron
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Antihyperalgesic Action of OFQ/N has shown that while m-sensitive NRM cells are acti-
vated during naloxone-precipitated hyperalgesia, activ-The antianalgesic effect of OFQ/N due to its inhibition
of NRM primary cells is only one part of OFQ/N actions ity of the NRM cells that are disinhibited by m opioids
(presumably equivalent to k-sensitive primary cells inon pain behavior. Previous studies show that increased
activity of m-sensitive NRM cells contributes to the hy- vitro) is mostly suppressed (Bederson et al., 1990). Un-
der such a condition, OFQ/N reduces the hyperalgesiaperalgesia observed during naloxone-precipitated opi-
oid abstinence in vivo (Bederson et al., 1990; Kaplan presumably by inhibiting the m-sensitive secondary
cells. The excitatory naloxone effect on primary cellsand Fields, 1991). Based on those observations, OFQ/N
inhibition of these cells (presumably equivalent to the following the morphine pretreatment in vitro is inconsis-
tent with its effect in the in vivo study, and the reasonm-sensitive secondary cells in vitro) should reduce the
hyperalgesia under similar conditions. Our subsequent for that is not clear. The cellular mechanism underlying
the excitatory effect of naloxone on chronic morphine-behavioral experiments confirm this hypothesis by
showing that the same NRM dose of OFQ/N that antago- treated cells is yet to be identified, and mechanisms of
opioid tolerance and consequent changes in responsesnizes the analgesic effect of PAG DAMGO produces an
antihyperalgesic, or a net analgesic effect in animals in a to naloxone remain to be further investigated.
hyperalgesic state during acute, naloxone-precipitated
opioid withdrawal. Thereby, OFQ/N can have opposite Function and Significance of OFQ/N Actions
actions on pain behavior when applied to the same brain Although no selective full antagonist for the OFQ/N re-
region under different behavioral conditions. In other ceptor is currently available, these OFQ/N actions in the
words, the OFQ/N action in the NRM on pain is depen- NRM are most likely mediated through this receptor.
dent on behavioral state. It is likely that testing OFQ/N This view is supported by the following: the resistance
effects in animals under different behavioral states has of these effects to all classic opioid receptor antagonists
contributed to the apparent inconsistencies in its action at both cellular and system levels, the lack of significant
on pain reported in previous studies (Henderson and OFQ/N affinity for the three classic opioid receptors
McKnight, 1997; Civelli et al., 1998; Darland et al., 1998; (Henderson and McKnight, 1997; Civelli et al., 1998), and
Yamamoto et al., 1999). the consistent pharmacological profile of the cellular
In an effort to determine the cellular mechanism for action of OFQ/N on various types of neurons throughout
the hyperalgesia during naloxone-precipitated opioid the brain (Henderson and McKnight, 1997; Darland et
withdrawal and consequently for the OFQ/N inhibition al., 1998).
of the hyperalgesia in the NRM, we have found that Based on previous evidence and our observations of
several hours of treatment with morphine in vitro induces antagonistic actions by OFQ/N on opioid effects under
a significant membrane hyperpolarization in primary two different behavioral conditions, that is, opioid anal-
cells. A similar inhibition of primary cells has been ob- gesia versus opioid withdrawal, it is likely that OFQ/N
served in NRM brain slices from rats that have been and its receptor function as an inhibitory modulator of
chronically treated with morphine in vivo and have devel- the opioid system for pain control, at least in the NRM.
oped behaviorally proven tolerance to morphine (Z. Z. P., Although it is not known whether the cellular mechanism
unpublished observations). The underlying mechanism for the bidirectional OFQ/N actions that we have de-
for the hyperpolarization is unknown and is currently scribed in the NRM is valid in other brain sites or in
under investigation. On the other hand, we have found the spinal cord, this mechanism probably does play an
that prolonged morphine pretreatment does not change important role in the pain-modulating actions of OFQ/N
the resting membrane potential in m-sensitive secondary applied systemically. Supporting evidence for that con-
cells although they are inhibited by acute m opioids in clusion includes the critical role of the NRM in CNS pain-
untreated slices. That demonstrates that these second- modulating networks at the supraspinal level (Basbaum
ary cells can develop tolerance following prolonged and Fields, 1984; Fields et al., 1991) and our finding that
morphine treatment in vitro. Subsequent addition of nal- OFQ/N applied locally into the NRM antagonizes the
oxone in morphine-treated slices to induced acute opi- hyperalgesia induced by morphine and naloxone admin-
oid withdrawal excites both cell types. We have ob- istered through a systemic route. Our demonstration
served a similar naloxone effect in the NRM slices from of an antihyperalgesic effect of OFQ/N during opioid
morphine-tolerant rats (Z. Z. P., unpublished observa- abstinence or withdrawal may be clinically significant
tions). A naloxone-induced depolarization has also been for the treatment of both drug addiction and pain. Thus,
reported in PAG neurons in vitro from chronic morphine- drugs targeting the OFQ/N system may have potential
treated rats (Chieng and Christie, 1996). to improve the treatment of opioid withdrawal as well
Although acute naloxone excites both primary and as of chronic pain conditions such as nerve injury or
secondary cell types in morphine-treated slices, it is inflammation where an NRM contribution to the sensi-
likely that the ultimate excitability or activity increase tized state has been demonstrated (Urban et al., 1999).
following naloxone would mostly occur in secondary
cells because primary cells have already been inhibited Experimental Procedures
(more negative resting membrane potentials) by the
Brain Slice Preparations and Morphine Treatmentmorphine pretreatment before naloxone. The relatively
Brainstem slices (200 mm thick) containing the NRM were cut fromlarger increase in the activity of m-sensitive secondary
a male neonatal (9±14 days old) Wistar rat brain in a vibratome in
cells produced by naloxone could then contribute to the cold physiological saline at 48C. A single slice was submerged in a
hyperalgesic effect observed during naloxone-precipi- shallow recording chamber through which flows the preheated
(358C) physiological saline (in mM: NaCl, 126; KCl, 2.5; NaH2PO4,tated opioid withdrawal in vivo. In fact, an in vivo study
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1.2; MgCl2, 1.2; CaCl2, 2.4; glucose, 11; NaHCO3, 25, saturated with Chen, Y., Fan, Y., Liu, J., Mestek, A., Tian, M., Kozak, C.A., and Yu,
L. (1994). Molecular cloning, tissue distribution and chromosomal95% O2 and 5% CO2). Neonatal rats were used for better visualization
of neurons with an infrared Nomarski microscope. It has been dem- localization of a novel member of the opioid receptor gene family.
FEBS Lett. 347, 279±283.onstrated that the physiological and pharmacological properties of
neurons from these young rats are indistinguishable from those of Chieng, B., and Christie, M.D. (1996). Local opioid withdrawal in
adult rats (Pan et al., 1997). rat single periaqueductal gray neurons in vitro. J. Neurosci. 16,
In some experiments, slices were incubated in the physiological 7128±7136.
saline containing 100 mM morphine for at least 2 hr before recording. Civelli, O., Nothacker, H.P., and Reinscheid, R. (1998). Reverse phys-
The same concentration of morphine was also present in the perfus- iology: discovery of the novel neuropeptide, orphanin FQ/nocicep-
ing solution throughout the experiment to prevent acute opioid with- tin. Crit. Rev. Neurobiol. 12, 163±176.
drawal.
Connor, M., Vaughan, C.W., Chieng, B., and Christie, M.J. (1996).
Nociceptin receptor coupling to a potassium conductance in rat
Whole-Cell Recording
locus coeruleus neurones in vitro. Brit. J. Pharmacol. 119, 1614±
Visualized whole-cell patch clamp recordings were made from an
1618.
identified neuron with a glass pipette (resistance 3±5 MV) filled with
Darland, T., Heinricher, M.M., and Grandy, D.K. (1998). Orphanina solution containing (mM): potassium gluconate, 126; NaCl, 10;
FQ/nociceptin: a role in pain and analgesia, but so much more.MgCl2, 1; EGTA, 11; HEPES, 10; ATP, 2; GTP, 0.25; pH adjusted to
Trends Neurosci. 21, 215±221.7.3 with KOH. A seal resistance of 5 GV or above and an access
Fields, H.L., Heinricher, M.M., and Mason, P. (1991). Neurotransmit-resistance of 15 MV or less were considered acceptable. Series
ters in nociceptive modulatory circuits. Annu. Rev. Neurosci. 14,resistance was optimally compensated by at least 70%. All drugs
219±245.were applied through the perfusing solution. Numeral data are pre-
sented as mean 6 SE. Fukuda, K., Kato, S., Mori, K., Nishi, M., Takeshima, H., Iwabe, N.,
Miyata, T., Houtani, T., and Sugimoto, T. (1994). cDNA cloning and
Behavioral Experiments and Microinjections regional distribution of a novel member of the opioid receptor family.
Male Wistar rats (300±350 g) were maintained lightly anesthetized FEBS Lett. 343, 42±46.
in a stereotaxic apparatus with a constant i.v. infusion of methohexi- Grudt, T.J., and Williams, J.T. (1995). Opioid receptors and the regu-
tal (10 mg/ml at 0.8 ml/hr). A 26-gauge single guide cannula was lation of ion conductances. Rev. Neurosci. 6, 279±286.
aimed at the ventrolateral PAG (AP, 27.8; L, 10.8; V, 26.0) and a
Heinricher, M.M., McGaraughty, S., and Grandy, D.K. (1997). Cir-
second, double guide cannula aimed at the NRM (AP, 211.0; L, 0;
cuitry underlying anti-opioid actions of orphanin FQ in the rostral
V, 210.7). Tail flick latency to a radiant heat stimulus was measured
ventromedial medulla. J. Neurophysiol. 78, 3351±3358.
every 2 min. The heat intensity was set to elicit stable baseline
Henderson, G., and McKnight, A.T. (1997). The orphan opioid recep-latencies between 5.0 and 6.5 s with a cutoff time of 12 or 15 s.
tor and its endogenous ligandÐnociceptin/orphanin FQ. TrendsAfter six baseline trials, drugs were delivered through a 33-gauge
Pharmacol. Sci. 18, 293±300.cannula with an infusion pump at a rate of 0.5 ml/min. Experiments
Kaplan, H., and Fields, H.L. (1991). Hyperalgesia during acute opioidof NRM placement control were conducted by aiming the NRM
abstinence: evidence for a nociceptive facilitating function of theguide cannula 1.5 mm above the normal designated area. All cannula
rostral ventromedial medulla. J. Neurosci. 11, 1433±1439.placements for both the PAG and the NRM were histologically veri-
fied afterwards, and only those located within the designated area King, M., Chang, A., and Pasternak, G.W. (1998). Functional block-
were included in the results. Drug effects were statistically con- ade of opioid analgesia by orphanin FQ/nociceptin. Biochem. Phar-
firmed by Student's t tests, an ANOVA for repeated measures, and macol. 55, 1537±1540.
the Tukey/Kramer procedure of post hoc analysis. Meis, S., and Pape, H.C. (1998). Postsynaptic mechanisms underly-
ing responsiveness of amygdaloid neurons to nociceptin/orphanin
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